Skip to content

A verification study of the immunostimulatory effects

A verification study of the immunostimulatory effects: a randomized, placebo-controlled, double-blind, parallel-group comparison study - A verification study of the immunostimulatory effects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052919
Enrollment
10
Registered
2024-11-21
Start date
2023-11-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: Four weeks Test food Duration: Four weeks Placebo food

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals who noticed any of the following symptoms in the last one month: whole body malaise, chilliness, feverishness, fatigue, sneezing, nasal discharge, nasal congestion, throat pain, cough, joint pain, and muscle pain

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking medications (including herbal medicines) and supplements 6. Individuals who are allergic to medicines and/or the test food related products (particularly salmon or gelatin) 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study 9. Individuals who are judged as ineligible to participate in this study by the physician 10. Individuals who have received vaccination for infectious diseases such as influenza within the last three months

Design outcomes

Primary

MeasureTime frame
1. The cumulative number of onset days with common cold-like symptoms* during the intervention period per participant * The common cold-like symptom is defined as the onset of more than one of the following symptoms in the diary: whole body malaise, chilliness, feverishness, fatigue, sneezing, nasal discharge, nasal congestion, throat pain, cough, joint pain, and muscle pain.

Secondary

MeasureTime frame
1. The maximum duration of the days with common cold-like symptoms* during the intervention period per participant 2. The measured value of the total immunoglobulin A (IgA) in the stool at four weeks after consumption (4w) 3. The measured values of scoring of immunological vigor, immunological grade, T lymphocyte age (upper limit and lower limit), percentage of CD3+T cells, number of CD3+T cells, scoring of number of CD3+T cells, percentage of CD4+T cells, number of CD4+T cells, percentage of CD8+T cells, number of CD8+T cells, CD4+T cells / CD8+T cells ratio, scoring of CD4+T cells / CD8+T cells ratio, percentage of naive T cells, number of naive T cells, scoring of number of naive T cells, percentage of memory T cells, number of memory T cells, naive T cells / memory T cells ratio, scoring of naive T cells / memory T cells ratio, percentage of CD56+16-natural killer (NK) cells, percentage of CD56+16+NK cells, number of NK cells, scoring of number of NK cells, percentage of B cells, number of B cells, scoring of number of B cells, percentage of CD8+CD28+T cells, number of CD8+CD28+T cells, and scoring of number of CD8+CD28+T cells at 4w 4. The measured values of vitality, appetite, skin condition measured by visual analog scale (VAS) at 4w * The common cold-like symptom is defined as the onset of more than one of the following symptoms in the diary: whole body malaise, chilliness, feverishness, fatigue, sneezing, nasal discharge, nasal congestion, throat pain, cough, joint pain, and muscle pain.

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026